Atopic Dermatitis - The Dermatology Digest

What is TSW? New Study Seeks Clarity on Topical Steroid Withdrawal

January 14, 2025

AD Pipeline Update: Target Enrollment Complete in Phase 2b Trial of Nectar’s Rezpegaldesleukin in AD

January 13, 2025

AD Pipeline Watch: CAGE Bio Initiates Phase 2b Trial for CGB-500, a Topical JAK Inhibitor for Moderate to Severe AD

January 10, 2025

Self-guided CBT May Help Ease Eczema

January 2, 2025

JNJ Continues to Grow AD Pipeline With New Licensing Agreement

December 27, 2024

Important Updates on the Efficacy and Safety of JAK Inhibitors in Dermatology

December 24, 2024

Advertisement

Latest Issue

Latest Supplements

Advertisement

Digital Edition Archive